KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Net Cash Flow (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Net Cash Flow for 13 consecutive years, with -$4.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 197.43% to -$4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.3 million through Dec 2025, down 281.65% year-over-year, with the annual reading at -$18.3 million for FY2025, 281.65% down from the prior year.
  • Net Cash Flow hit -$4.4 million in Q4 2025 for Arbutus Biopharma, up from -$15.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $46.9 million in Q3 2021 to a low of -$48.5 million in Q2 2021.
  • Historically, Net Cash Flow has averaged -$1.7 million across 5 years, with a median of $528500.0 in 2025.
  • Biggest YoY gain for Net Cash Flow was 606.5% in 2021; the steepest drop was 348.18% in 2021.
  • Year by year, Net Cash Flow stood at $31.4 million in 2021, then tumbled by 78.42% to $6.8 million in 2022, then increased by 28.98% to $8.7 million in 2023, then plummeted by 48.32% to $4.5 million in 2024, then tumbled by 197.43% to -$4.4 million in 2025.
  • Business Quant data shows Net Cash Flow for ABUS at -$4.4 million in Q4 2025, -$15.0 million in Q3 2025, and $315000.0 in Q2 2025.